MicroPort CardioFlow Medtech (2160) Stock Overview
A medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
2160 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MicroPort CardioFlow Medtech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.18 |
| 52 Week High | HK$1.69 |
| 52 Week Low | HK$0.63 |
| Beta | 0.44 |
| 1 Month Change | -9.23% |
| 3 Month Change | -20.27% |
| 1 Year Change | 73.53% |
| 3 Year Change | -55.47% |
| 5 Year Change | n/a |
| Change since IPO | -93.73% |
Recent News & Updates
Why We're Not Concerned Yet About MicroPort CardioFlow Medtech Corporation's (HKG:2160) 26% Share Price Plunge
Nov 04
Does MicroPort CardioFlow Medtech (HKG:2160) Have A Healthy Balance Sheet?
Oct 06Recent updates
Why We're Not Concerned Yet About MicroPort CardioFlow Medtech Corporation's (HKG:2160) 26% Share Price Plunge
Nov 04Does MicroPort CardioFlow Medtech (HKG:2160) Have A Healthy Balance Sheet?
Oct 06MicroPort CardioFlow Medtech Corporation's (HKG:2160) 50% Jump Shows Its Popularity With Investors
Jul 28Is There An Opportunity With MicroPort CardioFlow Medtech Corporation's (HKG:2160) 41% Undervaluation?
Jul 17MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 12Take Care Before Jumping Onto MicroPort CardioFlow Medtech Corporation (HKG:2160) Even Though It's 37% Cheaper
Apr 08Revenues Tell The Story For MicroPort CardioFlow Medtech Corporation (HKG:2160) As Its Stock Soars 29%
Feb 10MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable
Sep 27After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar
Sep 27Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?
Aug 07Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding
Jun 19MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
May 29MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 05We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued
Jan 18Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%
May 31We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts
Apr 06MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Jun 30Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Apr 04MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 03An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued
Jan 21Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?
Sep 05We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn
Jun 07Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)
May 03Shareholder Returns
| 2160 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 6.3% | 1.5% | 2.7% |
| 1Y | 73.5% | 67.0% | 41.9% |
Return vs Industry: 2160 exceeded the Hong Kong Medical Equipment industry which returned 67% over the past year.
Return vs Market: 2160 exceeded the Hong Kong Market which returned 41.9% over the past year.
Price Volatility
| 2160 volatility | |
|---|---|
| 2160 Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 2160 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2160's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 417 | Ruinian Zhang | www.cardioflowmedtech.com |
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valvular heart diseases, as well as properties management. It’s product portfolio includes transcatheter aortic valves, left atrial appendage closure, transcatheter mitral valves, transcatheter tricuspid valves, and surgical accessories, as well as procedural accessories; and VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex, Alwide Plus, AccuSniperTM, AnchorMan LAAC System, AnchorMan LAAA System, and various TAVI, TMV, TTV, and LAA products.
MicroPort CardioFlow Medtech Corporation Fundamentals Summary
| 2160 fundamental statistics | |
|---|---|
| Market cap | HK$2.85b |
| Earnings (TTM) | HK$5.31m |
| Revenue (TTM) | HK$402.45m |
Is 2160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2160 income statement (TTM) | |
|---|---|
| Revenue | CN¥367.53m |
| Cost of Revenue | CN¥113.62m |
| Gross Profit | CN¥253.91m |
| Other Expenses | CN¥249.06m |
| Earnings | CN¥4.85m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.002 |
| Gross Margin | 69.09% |
| Net Profit Margin | 1.32% |
| Debt/Equity Ratio | 11.5% |
How did 2160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 00:14 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MicroPort CardioFlow Medtech Corporation is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry He | CGS International |
| Bo Yu | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |